Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021)

A Walkty; J A Karlowsky; P R S Lagacé-Wiens; M R Baxter; H J Adam; D C Bay; G G Zhanel

doi:10.1016/j.diagmicrobio.2023.116130

Moving towards a standardized definition of antimicrobial resistance: a comparison of the antimicrobial susceptibility profile of difficult-to-treat resistance (DTR) versus multidrug-resistant (MDR) Pseudomonas aeruginosa clinical isolates (CANWARD, 2016-2021)

Diagn Microbiol Infect Dis. 2024 Feb;108(2):116130. doi: 10.1016/j.diagmicrobio.2023.116130. Epub 2023 Nov 17.

Authors

A Walkty¹, J A Karlowsky², P R S Lagacé-Wiens², M R Baxter³, H J Adam², D C Bay³, G G Zhanel³

Affiliations

¹ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada; Shared Health, Winnipeg, Canada. Electronic address: AWalkty@sharedhealthmb.ca.
² Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada; Shared Health, Winnipeg, Canada.
³ Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Canada.

PMID: 38006710
DOI: 10.1016/j.diagmicrobio.2023.116130

Abstract

Pseudomonas aeruginosa clinical isolates demonstrating difficult-to-treat resistance (DTR) and multidrug-resistant (MDR) phenotypes were evaluated by broth microdilution. Susceptibility was lower for all antimicrobials versus DTR relative to MDR isolates. Ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-relebactam susceptibility was 35.9%, 64.5%, and 47.0% for DTR isolates and 60.5%, 80.6%, and 71.5% for MDR isolates.

Keywords: Difficult-to-treat; Multidrug-resistant; Pseudomonas aeruginosa.

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Anti-Infective Agents* / pharmacology
Azabicyclo Compounds / pharmacology
Azabicyclo Compounds / therapeutic use
Ceftazidime / pharmacology
Ceftazidime / therapeutic use
Cephalosporins / pharmacology
Cephalosporins / therapeutic use
Drug Combinations
Drug Resistance, Bacterial
Drug Resistance, Multiple, Bacterial
Humans
Microbial Sensitivity Tests
Pseudomonas Infections* / drug therapy
Pseudomonas aeruginosa

Substances

Anti-Bacterial Agents
Ceftazidime
Cephalosporins
Anti-Infective Agents
Azabicyclo Compounds
Drug Combinations